Evaluating elexacaftor/tezacaftor/ivacaftor (ETI; Trikafta™) for treatment of patients with non-cystic fibrosis bronchiectasis (NCFBE): A clinical study protocol.
<h4>Background</h4>Non-cystic fibrosis bronchiectasis (NCFBE) is a disease that exhibits dilatation of airways, airflow obstruction, persistent cough, excessive sputum production, and refractory respiratory infections. NCFBE exhibits clinical and pathological manifestations similar to ke...
Saved in:
| Main Authors: | Colin E Swenson, William R Hunt, Candela Manfredi, Diana J Beltran, Jeong S Hong, Brian R Davis, Shingo Suzuki, Cristina Barillá, Andras Rab, Cynthia Chico, Joy Dangerfield, Ashleigh Streby, Erin Barton, Elizabeth M Cox, Arlene A Stecenko, Adrianna Westbrook, Rebecca Kapolka, Eric J Sorscher |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0316721 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation
by: Steven J Edwards, et al.
Published: (2025-05-01) -
Impact of elexacaftor/tezacaftor/ivacaftor on the small airways in cystic fibrosis
by: Sofia Campos Silva, et al.
Published: (2025-06-01) -
Impact of elexacaftor/tezacaftor/ivacaftor (ETI) on the prescription refill rate (PRR) for inhaled medications in people with CF: an Italian multicenter analysis
by: Andrea Gramegna, et al.
Published: (2025-01-01) -
Proteomics profiling of inflammatory responses to elexacaftor/tezacaftor/ivacaftor in cystic fibrosis
by: Hazel Ozuna, et al.
Published: (2025-01-01) -
Unveiling the psychosocial impact of Elexacaftor/Tezacaftor/Ivacaftor therapy in Cystic Fibrosis patients
by: Marta Solís García, et al.
Published: (2025-02-01)